

according to the OSHA Hazard Communication Standard

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
6.1	09/30/2023	402657-00020	Date of first issue: 12/11/2015

SECTION 1. IDENTIFICATION

Product name	:	Ribavirin Solid Formulation			
Manufacturer or supplier's	deta	ails			
Company name of supplier	:	Merck & Co., Inc			
Address		126 E. Lincoln Avenue			
		Rahway, New Jersey U.S.A. 07065			
Telephone	:	908-740-4000			
Emergency telephone	:	1-908-423-6000			
E-mail address	:	EHSDATASTEWARD@merck.com			
Recommended use of the chemical and restrictions on use					
Recommended use	:	Pharmaceutical			

Not applicable

:

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR
1910.1200)

Combustible dust

Restrictions on use

Germ cell mutagenicity	:	Category 2
Reproductive toxicity	:	Category 1B
Specific target organ toxicity - single exposure	:	Category 3
Specific target organ toxicity - repeated exposure (Oral)	:	Category 1 (Blood)
GHS label elements Hazard pictograms	:	
Signal Word	:	Danger
Hazard Statements	:	If small particles are generated during further processing, han- dling or by other means, may form combustible dust concentra- tions in air. H335 May cause respiratory irritation. H341 Suspected of causing genetic defects.

H341 Suspected of causing genetic defects. H360Df May damage the unborn child. Suspected of damaging fertility.

H372 Causes damage to organs (Blood) through prolonged or repeated exposure if swallowed.





Ribavirin Solid Formulation

rsion Revision 09/30/20		Date of last issue: 04/04/2023 Date of first issue: 12/11/2015
Precautionary S	Prevention P201 Obtair P202 Do no and underst P260 Do no P264 Wash P270 Do no P271 Use o	n special instructions before use. t handle until all safety precautions have been read ood. t breathe dust. skin thoroughly after handling. t eat, drink or smoke when using this product. nly outdoors or in a well-ventilated area. protective gloves, protective clothing, eye protection
	and keep co unwell.	0 + P312 IF INHALED: Remove person to fresh air omfortable for breathing. Call a doctor if you feel 3 IF exposed or concerned: Get medical attention.
	Storage: P405 Store	locked up.
	Disposal: P501 Dispos disposal pla	se of contents and container to an approved waste nt.
	•	nt.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture	:	Mixture

Components

91-04-5 >= 50 - < 70
4-34-6 >= 10 - < 20
04-0 >= 1 - < 5

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention.



Ribavirin Solid Formulation

Version 6.1	Revision Date: 09/30/2023	SDS Number: 402657-00020	Date of last issue: 04/04/2023 Date of first issue: 12/11/2015		
	se of eye contact allowed	Thoroughly clea If in eyes, rinse Get medical atte If swallowed, DC	Wash clothing before reuse. Thoroughly clean shoes before reuse. If in eyes, rinse well with water. Get medical attention if irritation develops and persists. If swallowed, DO NOT induce vomiting.		
and	t important symptoms effects, both acute and	: May cause resp Suspected of ca	roughly with water.		
delayed		ty. Causes damage exposure if swal	to organs through prolonged or repeated		
Prote	ection of first-aiders	: First Aid respond and use the reco	h the eyes can lead to mechanical irritation. ders should pay attention to self-protection, promended personal protective equipment		
Note	s to physician		ial for exposure exists (see section 8). tically and supportively.		

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides Metal oxides
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so.



Ribavirin Solid Formulation

Version 6.1	Revision Date: 09/30/2023	SDS Number: 402657-00020	Date of last issue: 04/04/2023 Date of first issue: 12/11/2015
			spose of contaminated wash water. es should be advised if significant spillages tained.
	ods and materials for inment and cleaning up	over the area Add excess lid Soak up with i Avoid dispersa with compress Dust deposits surfaces, as th released into the Clean up rema absorbent. Local or nation disposal of thi employed in the determine white Sections 13 at	with absorbents and place a damp covering to minimize entry of the material into the air. quid to allow the material to enter into solution. nert absorbent material. al of dust in the air (i.e., clearing dust surfaces sed air). should not be allowed to accumulate on nese may form an explosive mixture if they are the atmosphere in sufficient concentration. aining materials from spill with suitable hal regulations may apply to releases and s material, as well as those materials and items he cleanup of releases. You will need to ch regulations are applicable. nd 15 of this SDS provide information regarding r national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Ventilation. Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the
Conditions for safe storage	:	environment. Keep in properly labeled containers. Store locked up. Keep tightly closed.



Ribavirin Solid Formulation

Version	Revision Date: 09/30/2023	SDS Number:	Date of last issue: 04/04/2023
6.1		402657-00020	Date of first issue: 12/11/2015
Mate	rials to avoid	Store in accord Do not store w Strong oxidizin	ubstances and mixtures

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

ingreatents with workplace co	
inert or nuisance dust	50 Million particles per cubic foot Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	15 mg/m³ Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	5 mg/m³ Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3
	15 Million particles per cubic foot Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3
Dust, nuisance dust and par- ticulates	10 mg/m³ Value type (Form of exposure): PEL (Total dust) Basis: CAL PEL

 $5~\text{mg/m}^3$ Value type (Form of exposure): PEL (respirable dust fraction) Basis: CAL PEL

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Ribavirin	36791-04-5	Wipe limit	400 µg/100 cm ²	Internal
		TWA	40 µg/m3 (OEB 3)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Res- pirable)	5 mg/m³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m³	OSHA Z-1
		TWA (respir- able fraction)	5 mg/m³	OSHA Z-1
Magnesium stearate	557-04-0	TWA (Inhal- able particu- late matter)	10 mg/m ³	ACGIH



according to the OSHA Hazard Communication Standard

sion	Revision Date: 09/30/2023		SDS Number:Date of last issue: 04/04/2023402657-00020Date of first issue: 12/11/2015				
			TWA (Res- pirable par- ticulate mat- ter)3 mg/m³ACGIH				
Engir	neering measures		All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.				
Perso	onal protective equip	ment					
Respi	iratory protection		General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.				
Hand	protection						
Ма	aterial	:	Chemical-resistant gloves				
	emarks protection	:	Consider double gloving. Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.				
Skin a	and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.				
Hygie	ne measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.				



according to the OSHA Hazard Communication Standard

Version 6.1	Revision Date: 09/30/2023		S Number: 2657-00020	Date of last issue: 04/04/2023 Date of first issue: 12/11/2015
SECTION	9. PHYSICAL AND CH	ΞΜΙΟ		 S
Арре	earance	:	powder	
Color	r	:	white	
Odor		:	No data available	e
Odor	Threshold	:	No data available	e
pН		:	No data available	e
Melti	ng point/freezing point	:	No data available	e
Initial range	l boiling point and boiling e	:	No data available	e
Flash	n point	:	No data available	e
Evap	oration rate	:	Not applicable	
Flam	mability (solid, gas)	:	May form explos handling or othe	ive dust-air mixture during processing, r means.
Flam	mability (liquids)	:	No data available	e
	er explosion limit / Upper nability limit	:	No data available	e
	er explosion limit / Lower nability limit	:	No data available	e
Vapo	or pressure	:	Not applicable	
Relat	tive vapor density	:	Not applicable	
Relat	tive density	:	No data available	e
Dens	sity	:	No data available	e
	bility(ies) /ater solubility	:	No data available	e
	tion coefficient: n-	:	Not applicable	
	nol/water ignition temperature	:	No data available	e
Deco	omposition temperature	:	No data available	e
Visco Vi	osity iscosity, kinematic	:	Not applicable	
Explo	osive properties	:	Not explosive	



	Revision Date: 09/30/2023		S Number: 2657-00020	Date of last issue: 04/04/2023 Date of first issue: 12/11/2015
Oxidiz	ring properties	:	The substance	or mixture is not classified as oxidizing.
Partic	le size	:	No data availat	ble
	10. STABILITY AND RE	EAC		
React Chem			Not classified a Stable under no May form explo handling or othe	s a reactivity hazard. ormal conditions. sive dust-air mixture during processing, er means. strong oxidizing agents.
Condi	tions to avoid	:	Heat, flames ar Avoid dust form	
	patible materials dous decomposition cts	:	Oxidizing agent	
Inhala Skin c Ingest	contact tion	of e	exposure	
Inhala Skin c Ingest Eye c	tion contact tion ontact	ofe	exposure	
Inhala Skin c Ingest Eye c Acute	tion contact tion ontact toxicity			
Inhala Skin c Ingest Eye c Acute	ition contact tion ontact toxicity assified based on availa			
Inhala Skin o Ingest Eye o Acute Not cl	ition contact tion ontact toxicity assified based on availa		information.	timate: 2,249 mg/kg tion method
Inhala Skin c Ingest Eye c Acute Not cl <u>Produ</u> Acute	ition contact tion ontact toxicity assified based on availa		information. Acute toxicity es	
Inhala Skin c Ingest Eye c Acute Not cl Produ Acute	ition contact tion ontact toxicity assified based on availa <u>ict:</u> oral toxicity <u>conents:</u>	ble :	information. Acute toxicity es Method: Calcula	ition method
Inhala Skin c Ingest Eye c Acute Not cl Produ Acute	ition contact tion ontact toxicity assified based on availa <u>uct:</u> oral toxicity	ble :	information. Acute toxicity es	ition method
Inhala Skin c Ingest Eye c Acute Not cl Produ Acute	ition contact tion ontact toxicity assified based on availa <u>ict:</u> oral toxicity <u>conents:</u>	ble :	information. Acute toxicity es Method: Calcula	ition method 16 - 5,584 mg/kg
Inhala Skin c Ingest Eye c Acute Not cl Produ Acute	ition contact tion ontact toxicity assified based on availa <u>ict:</u> oral toxicity <u>conents:</u>	ble :	information. Acute toxicity es Method: Calcula LD50 (Rat): 4,1 ²	16 - 5,584 mg/kg > 10,000 mg/kg
Inhala Skin c Ingest Eye c Acute Not cl <u>Produ</u> Acute	ition contact tion ontact toxicity assified based on availa <u>ict:</u> oral toxicity <u>conents:</u>	ble :	information. Acute toxicity es Method: Calcula LD50 (Rat): 4,12 LD50 (Mouse): :	16 - 5,584 mg/kg > 10,000 mg/kg 1,500 mg/kg
Inhala Skin c Ingest Eye c Acute Not cl <u>Produ</u> Acute Comp Ribav Acute	tion contact tion ontact toxicity assified based on availa <u>act:</u> oral toxicity conents: ririn: oral toxicity	ble :	information. Acute toxicity es Method: Calcula LD50 (Rat): 4,17 LD50 (Mouse): = LD50 (Dog): >= Remarks: No da	16 - 5,584 mg/kg > 10,000 mg/kg 1,500 mg/kg Ita available
Inhala Skin c Ingest Eye c Acute Not cl Produ Acute Comp Ribav Acute Acute Acute	inhalation toxicity	ble : :	information. Acute toxicity es Method: Calcula LD50 (Rat): 4,17 LD50 (Mouse): 3 LD50 (Dog): >= Remarks: No da Remarks: No da LD50 (Rat): 1,55	16 - 5,584 mg/kg > 10,000 mg/kg 1,500 mg/kg Ita available



according to the OSHA Hazard Communication Standard

sion	Revision Date: 09/30/2023	SDS Nu 402657		Date of last issue: 04/04/2023 Date of first issue: 12/11/2015
		Арр	lication Route	e: Intraperitoneal
Cellu	lose:			
Acute	oral toxicity	: LD5	50 (Rat): > 5,0	000 mg/kg
Acute	inhalation toxicity	Exp	50 (Rat): > 5.8 oosure time: 4 t atmosphere	h
Acute	e dermal toxicity	: LD5	50 (Rabbit): >	2,000 mg/kg
Magn	esium stearate:			
-	oral toxicity	Met Ass icity	essment: The	000 mg/kg Fest Guideline 423 e substance or mixture has no acute oral to on data from similar materials
Acute	e dermal toxicity		50 (Rabbit): >	
-	corrosion/irritation assified based on ava			on data from similar materials
Not cl <u>Comp</u> Ribay	lassified based on ava ponents: /irin:	ailable infor	mation.	
Not cl Comp	lassified based on ava ponents: /irin:	ailable infor		
Not cl <u>Comp</u> Ribav Rema	lassified based on ava ponents: /irin:	ailable infor	mation. data available	
Not cl Comp Ribay Rema Magn Speci	lassified based on ava <u>conents:</u> virin: arks esium stearate: es	ailable inforn : No May : Rab	mation. data available y irritate skin. obit	
Not cl Comp Ribav Rema Magn Speci Resul	lassified based on ava <u>ponents:</u> virin: arks hesium stearate : es It	ailable infor : No May : Rat : No	mation. data available y irritate skin. obit skin irritation)
Not cl Comp Ribay Rema Magn Speci	lassified based on ava <u>ponents:</u> virin: arks hesium stearate : es It	ailable infor : No May : Rat : No	mation. data available y irritate skin. obit skin irritation	
Not cl Comp Ribav Rema Magn Speci Resul Rema Serio	lassified based on ava <u>conents:</u> virin: arks esium stearate: es lt arks us eye damage/eye	ailable infor : No (May : Rab : No : : Bas irritation	mation. data available y irritate skin. obit skin irritation sed on data fre)
Not cl Comp Ribay Rema Magn Speci Resul Rema Serio Not cl	lassified based on ava <u>conents:</u> virin: arks esium stearate: es It arks us eye damage/eye lassified based on ava	ailable infor : No (May : Rab : No : : Bas irritation	mation. data available y irritate skin. obit skin irritation sed on data fre)
Not cl Comp Ribay Rema Magn Speci Resul Rema Serio Not cl	lassified based on ava <u>conents:</u> virin: arks esium stearate: es lt arks us eye damage/eye	ailable infor : No (May : Rab : No : : Bas irritation	mation. data available y irritate skin. obit skin irritation sed on data fre)
Not cl Comp Ribav Rema Magn Speci Resul Rema Serio Not cl <u>Comp</u> Ribav	lassified based on ava <u>conents:</u> virin: arks es t arks us eye damage/eye lassified based on ava <u>conents:</u> virin:	ailable infor : No (May : Rab : No : : Bas i rritation ailable infor	mation. data available y irritate skin. obit skin irritation sed on data fro mation.	om similar materials
Not cl Comp Ribay Rema Magn Speci Resul Rema Serio Not cl <u>Comp</u>	lassified based on ava <u>conents:</u> virin: arks es t arks us eye damage/eye lassified based on ava <u>conents:</u> virin:	ailable inform : No (May : Rab : No : i rritation ailable inform	mation. data available y irritate skin. obit skin irritation sed on data fre	e om similar materials
Not cl Comp Ribav Rema Magn Speci Resul Rema Serio Not cl <u>Comp</u> Ribav Rema	lassified based on ava <u>conents:</u> virin: arks esium stearate: es t arks us eye damage/eye lassified based on ava <u>conents:</u> virin: arks	ailable inform : No (May : Rab : No : i rritation ailable inform	mation. data available y irritate skin. obit skin irritation sed on data fre mation. data available	e om similar materials
Not cl Comp Ribav Rema Speci Resul Resul Rema Serio Not cl Comp Ribav Rema	lassified based on ava <u>conents:</u> virin: arks esium stearate: es t arks us eye damage/eye lassified based on ava <u>conents:</u> virin: arks esium stearate:	ailable inform : No (May : Rab : No : i rritation ailable inform	mation. data available y irritate skin. obit skin irritation sed on data fro mation. data available y irritate eyes.	e om similar materials
Not cl Comp Ribav Rema Magn Speci Resul Rema Serio Not cl <u>Comp</u> Ribav Rema	lassified based on ava <u>conents:</u> virin: arks esium stearate: es lt arks us eye damage/eye lassified based on ava <u>conents:</u> virin: arks esium stearate: es lt	ailable inform : No (May : Rab : No (: Bas irritation ailable inform : No (May : Rab : No (mation. data available y irritate skin. obit skin irritation sed on data fro mation. data available y irritate eyes.	e om similar materials



according to the OSHA Hazard Communication Standard

Ver 6.1	sion	Revision Date: 09/30/2023		DS Number: 2657-00020	Date of last issue: 04/04/2023 Date of first issue: 12/11/2015
	Respi	ratory or skin sensitiz	atic	on	
		ensitization assified based on availa	able	information.	
	-	ratory sensitization assified based on availa	able	information.	
	<u>Comp</u>	onents:			
	Ribav Rema		:	No data available	
	Test T	s of exposure es d		Maximization Tes Skin contact Guinea pig OECD Test Guide negative Based on data fro	
	Suspe	cell mutagenicity cted of causing genetic onents:	c def	ects.	
	Ribav Genot	irin: oxicity in vitro	:	Test Type: Bacter Result: negative	ial reverse mutation assay (AMES)
				Test Type: In vitro Test system: Rod Result: positive	o mammalian cell gene mutation test ent cell line
				Test Type: Chrom Test system: Hum Result: negative	nosomal aberration nan lymphocytes
	Genot	oxicity in vivo	:	Test Type: domin Species: Rat Result: negative	ant lethal test
				Test Type: Mouse Species: Mouse Result: positive	e Lymphoma
				Test Type: Micror Species: Mouse Result: positive	nucleus test
	Germ Asses	cell mutagenicity - sment	:	Positive result(s) genicity tests.	from in vivo mammalian somatic cell muta-



according to the OSHA Hazard Communication Standard

Ribavirin Solid Formulation

ersion 1	Revision Date: 09/30/2023	SDS Number: 402657-00020	Date of last issue: 04/04/2023 Date of first issue: 12/11/2015
Cellu	llose:		
Genc	otoxicity in vitro	: Test Type: B Result: nega	acterial reverse mutation assay (AMES) tive
		Test Type: In Result: nega	vitro mammalian cell gene mutation test
Genc	otoxicity in vivo	cytogenetic a Species: Mor	use Route: Ingestion
Magr	nesium stearate:		
Geno	otoxicity in vitro	Result: nega	vitro mammalian cell gene mutation test tive sed on data from similar materials
		Method: OEC Result: nega	
		Remarks: Ba	sed on data from similar materials
		Result: nega	acterial reverse mutation assay (AMES) tive sed on data from similar materials
Carc	inogenicity		
Not c	lassified based on av	ailable information.	
Com	ponents:		
	virin:		
Spec Appli	ies cation Route	: Mouse : Oral	
Expo	sure time	: 6 Months	
LOAE		: 75 mg/kg boo	dy weight
Resu Targe	iit et Organs	: negative : Blood, Teste	S
Rema			sm or mode of action may not be relevant in hu
Spec	ies	: Rat	
A	antion llout-		

 Application Route
 :
 Oral

 Exposure time
 :
 2 Years

 NOAEL
 :
 10 mg/kg body weight


 Result
 :
 negative

 Remarks
 :
 The mechanism or mode of action may not be relevant in humans.

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	18 Months



Version 6.1	Revision Date: 09/30/2023	SDS Number: 402657-00020	Date of last issue: 04/04/2023 Date of first issue: 12/11/2015
Resu Rema		: negative : The mechanis mans.	m or mode of action may not be relevant in hu-
	ies cation Route sure time	: Rat : Ingestion : 72 weeks : negative	
IARC			sent at levels greater than or equal to 0.1% is or confirmed human carcinogen by IARC.
OSH		oonent of this product pro A's list of regulated carci	esent at levels greater than or equal to 0.1% is nogens.
NTP		dient of this product pres d as a known or anticipat	sent at levels greater than or equal to 0.1% is ed carcinogen by NTP.
Riba v Effec	ts on fertility	Fertility: LOAE Symptoms: Re	male oute: Intraperitoneal injection L: < 20 mg/kg body weight educed fertility
		Fertility: LOAE	L: < 20 mg/kg body weight educed fertility e rtility se, male
		Fertility: LOAE Symptoms: Re Result: positiv	
			females
			male
Effec	ts on fetal developr	nent : Test Type: De Species: Rat,	





Versior 6.1	n Revision Date: 09/30/2023		0S Number: 2657-00020	Date of last issue: 04/04/2023 Date of first issue: 12/11/2015
			Symptoms: Reduction fetuses., Skeletal	oxicity: LOAEL: <= 1 mg/kg body weight ced body weight, Reduced number of viable malformations. kic effects and adverse effects on the
			Developmental To Symptoms: Reduc	emale : Oral Maternal: LOAEL: 1 mg/kg body weight oxicity: LOAEL: 1 mg/kg body weight ced body weight, Skeletal malformations. kic effects and adverse effects on the
			Symptoms: Skele tions / resorption	: Oral oxicity: LOAEL: 2.5 mg/kg body weight tal and visceral variations ., Total Resorp- rate. kic effects and adverse effects on the
			Species: Rat Application Route General Toxicity M Embryo-fetal toxic	o-fetal development : Oral Maternal: NOAEL: 0.3 mg/kg body weight sity.: LOAEL: 1 mg/kg body weight tal malformations.
	eproductive toxicity - As- ssment	:	fertility, based on	f adverse effects on sexual function and animal experiments., Clear evidence of n development, based on animal
Ce	ellulose:			
	fects on fertility	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study : Ingestion
Ef	fects on fetal development	:	Test Type: Fertilit Species: Rat Application Route Result: negative	y/early embryonic development : Ingestion
Ma	agnesium stearate:			
	fects on fertility	:		ned repeated dose toxicity study with the elopmental toxicity screening test



according to the OSHA Hazard Communication Standard

Version 6.1	Revision Date: 09/30/2023)S Number: 2657-00020	Date of last issue: 04/04/2023 Date of first issue: 12/11/2015
			Result: negative	Test Guideline 422
Effec	Effects on fetal development		Species: Rat Application Rout Result: negative	
May	T-single exposure cause respiratory irritatio ponents:	n.		
	avirin: essment	:	May cause respi	ratory irritation.
Caus	STOT-repeated exposure Causes damage to organs (Blo <u>Components:</u> Ribavirin:		l) through prolong	ed or repeated exposure if swallowed.
Rout Targ	ivirin: tes of exposure let Organs essment	:	Ingestion Blood Causes damage exposure.	to organs through prolonged or repeated
Rep	eated dose toxicity			
Com	ponents:			
Spec LOA Expo		: :	Monkey 30 mg/kg 10 d Blood, Gastroint	estinal tract
Expo		: : :	Rat 7.6 mg/kg Inhalation 90 d Blood, Lungs	
Expo		: : : : :	Dog 5 mg/kg Oral 1 y Blood, Gastroint	estinal tract



according to the OSHA Hazard Communication Standard

1	Revision Date: 09/30/2023	SDS Number: 402657-00020	Date of last issue: 04/04/2023 Date of first issue: 12/11/2015
Expo		: Mouse : 20 mg/kg : Oral : 18 Months : Blood, Cardie	o-vascular system
Cellu	llose:		
		: Rat : >= 9,000 mg : Ingestion : 90 Days	/kg
Magr	nesium stearate:		
	EL cation Route sure time	: Rat : > 100 mg/kg : Ingestion : 90 Days : Based on da	ta from similar materials
Aspi	ration toxicity		
Not c	lassified based on ava	ilable information.	
Expe	rience with human e	xposure	
<u>Com</u>	ponents:		
Riba	virin:		
Inhala	ation		leadache, Dizziness
Skin	contact	: Remarks: Ma	ised on Human Evidence ay cause eye irritation. Iman Evidence
	a set a st		ay cause eye irritation. Iman Evidence
Eye c	contact	Based on Hu	

<u>Components:</u>		
Ribavirin:		
Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 119 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 117 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 119



according to the OSHA Hazard Communication Standard

Version 6.1	Revision Date: 09/30/2023		0S Number: 2657-00020	Date of last issue: 04/04/2023 Date of first issue: 12/11/2015
plan	ts		mg/l Exposure time: 96 Method: OECD To	
			NOEC (Pseudokin mg/l Exposure time: 96 Method: OECD To	
Toxi	icity to microorganisms	:	EC50: > 1,000 mg Exposure time: 3 Test Type: Respir Method: OECD To	h ation inhibition
Cell	ulose:			
Tox	icity to fish	:	Exposure time: 48	ipes (Japanese medaka)): > 100 mg/l 3 h on data from similar materials
Мас	nesium stearate:			
Toxi	icity to fish	:	Exposure time: 48 Method: DIN 384	
	icity to daphnia and other atic invertebrates	:	Exposure time: 47 Test substance: V Method: Directive	Vater Accommodated Fraction 67/548/EEC, Annex V, C.2. on data from similar materials
	icity to algae/aquatic ts	:	mg/l Exposure time: 72 Test substance: V Method: OECD To	Vater Accommodated Fraction est Guideline 201 on data from similar materials
			mg/l Exposure time: 72 Test substance: V Method: OECD To	Vater Accommodated Fraction
Toxi	icity to microorganisms	:	Exposure time: 16 Test substance: V	nas putida): > 100 mg/l 5 h Vater Accommodated Fraction on data from similar materials



according to the OSHA Hazard Communication Standard

Ribavirin Solid Formulation

Version 6.1	Revision Date: 09/30/2023		DS Number: 2657-00020	Date of last issue: 04/04/2023 Date of first issue: 12/11/2015
Pers	istence and degradal	bility		
<u>Com</u>	ponents:			
Cellu	llose:			
Biode	egradability	:	Result: Readily b	biodegradable.
	n esium stearate: egradability	:	Result: Not biode Remarks: Based	egradable on data from similar materials
Bioa	ccumulative potentia	I		
<u>Com</u>	ponents:			
Riba	virin:			
	tion coefficient: n- nol/water	:	log Pow: 0.971	
-	nesium stearate:			
	tion coefficient: n- nol/water	:	log Pow: > 4	
Mobi	lity in soil			
No da	ata available			
	r adverse effects			
No da	ata available			

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods		
Waste from residues	:	Dispose of in accordance with local regulations.
		Do not dispose of waste into sewer.
Contaminated packaging	:	
		handling site for recycling or disposal.
		If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR


Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.





Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
6.1	09/30/2023	402657-00020	Date of first issue: 12/11/2015

Domestic regulation

49 CFR Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	Combustible dust Germ cell mutagenicity Reproductive toxicity Specific target organ toxicity (single or repeated exposure)
SARA 313 :	This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know	
Ribavirin	36791-04-5
Cellulose	9004-34-6
D-Glucose, 4-O-β-D-galactopyranosyl-, monohydrate	64044-51-5

California Prop. 65

WARNING: This product can expose you to chemicals including Ribavirin, which is/are known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.

California List of Hazardous	s Substances					
Ribavirin		36791-04-5				
California Permissible Exposure Limits for Chemical Contaminants						
Cellulose		9004-34-6				
Magnesium stearat	e	557-04-0				
The ingredients of this prod	luct are reported in the following inv	entories:				
AICS	: not determined					
DSL	: not determined					

IECSC	:	not determined






Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
6.1	09/30/2023	402657-00020	Date of first issue: 12/11/2015

SECTION 16. OTHER INFORMATION



AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
6.1	09/30/2023	402657-00020	Date of first issue: 12/11/2015

in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance: PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Material Safety Data Sheet		eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/
Data Sheet		cy, http://echa.europa.eu/

Revision Date : 09/30/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8